We noticed that compared with the normal tissues, GLS2 is considerably over-expressed in bladder, colon, rectum, head-and-neck, peritoneum, and lung cancers, whereas it is under-expressed in brain, liver, and pancreatic cancer (Figure 3a(i–ix)) [30,33,39,44,45,46,47,48], according to the Oncomine-aided gene expression investigation. Here, GLS2 is linked to lung carcinoma.